Novartis's Ultibro Breezhaler shows minor additional benefit, says IQWiG
This article was originally published in Scrip
Executive Summary
Germany's health technology assessment body, IQWiG, has said Novartis's COPD treatment Ultibro Breezhaler (indacaterol/glycopyrronium) offers a minor additional benefit over comparator therapies, a positive outcome but not overwhelmingly so. It means that Novartis should be able to negotiate a satisfactory price for the product in Germany, but perhaps not such a high price as the company would like.